Equity Overview
Price & Market Data
Price: $8.22
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $26,352,160
Daily Volume: 0
Performance Metrics
1 Week: 32.93%
1 Month: -2.20%
3 Months: -49.01%
6 Months: 3.33%
1 Year: 17.32%
YTD: -30.38%
Company Details
Employees: 24
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.